Literature DB >> 16715389

Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389.

Sherif I Farag Badawy1, David B Gray, Fang Zhao, Duxin Sun, Alan E Schuster, Munir A Hussain.   

Abstract

PURPOSE: The purpose of the study was to investigate the specific mechanism by which elevated gastric pH reduces the absorption of BMS-561389, a factor Xa inhibitor, and to develop a solid formulation strategy to overcome this gastric pH interaction.
METHODS: A dissolution method in an acetate buffer at pH 5.5 was used to evaluate the dissolution behavior of the tablet formulation. A precipitation model was used to screen different excipients for their potential to minimize the pH-dependent absorption of BMS-561389. Excipients that showed promise in the precipitation model were incorporated in modified tablet formulations. Dissolution rate of the modified tablets was also determined by the acetate buffer method. A canine model for pH-dependent absorption was subsequently used to evaluate the tablet formulations.
RESULTS: Dissolution studies suggested that the reduced absorption of the original formulation was the result of the precipitation of the poorly water-soluble free base during the initial dissolution of the salt. Modified tablets containing organic acids, sulfobutylether-beta-cyclodextrin, or povidone showed enhanced dissolution as compared with the original formulation. Drug absorption from the tablet containing tartaric acid was substantially independent of gastric pH in the canine model.
CONCLUSION: A multitier approach was successful in identifying a solid dosage form that minimizes the pH-dependent absorption of this drug candidate.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16715389     DOI: 10.1007/s11095-006-9899-z

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

1.  Changes in the oral absorption characteristics in man of dipotassium clorazepate at normal and elevated gastric pH.

Authors:  C W Abruzzo; T Macasieb; R Weinfeld; J A Rider; S A Kaplan
Journal:  J Pharmacokinet Biopharm       Date:  1977-08

2.  Gastric pH profiles of beagle dogs and their use as an alternative to human testing.

Authors:  M Akimoto; N Nagahata; A Furuya; K Fukushima; S Higuchi; T Suwa
Journal:  Eur J Pharm Biopharm       Date:  2000-03       Impact factor: 5.571

3.  Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.

Authors:  Mimi L Quan; Patrick Y S Lam; Qi Han; Donald J P Pinto; Ming Y He; Renhua Li; Christopher D Ellis; Charles G Clark; Christopher A Teleha; Jung-Hui Sun; Richard S Alexander; Steve Bai; Joseph M Luettgen; Robert M Knabb; Pancras C Wong; Ruth R Wexler
Journal:  J Med Chem       Date:  2005-03-24       Impact factor: 7.446

4.  Effect of food and gastric acidity on absorption of orally administered ketoconazole.

Authors:  P Lelawongs; J A Barone; J L Colaizzi; A T Hsuan; W Mechlinski; R Legendre; J Guarnieri
Journal:  Clin Pharm       Date:  1988-03

5.  pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model.

Authors:  Rong Zhou; Paul Moench; Christopher Heran; Xujin Lu; Neil Mathias; Teresa N Faria; Doris A Wall; Munir A Hussain; Ronald L Smith; Duxin Sun
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

6.  Doxycycline carrageenate--an improved formulation providing more reliable absorption and plasma concentrations at high gastric pH than doxycycline monohydrate.

Authors:  A Grahnén; B Olsson; G Johansson; S A Eckernäs
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

7.  Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans.

Authors:  C Y Lui; G L Amidon; R R Berardi; D Fleisher; C Youngberg; J B Dressman
Journal:  J Pharm Sci       Date:  1986-03       Impact factor: 3.534

8.  pH-related changes in the absorption of dipyridamole in the elderly.

Authors:  T L Russell; R R Berardi; J L Barnett; T L O'Sullivan; J G Wagner; J B Dressman
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

  8 in total
  13 in total

Review 1.  Impact of excipient interactions on solid dosage form stability.

Authors:  Ajit S Narang; Divyakant Desai; Sherif Badawy
Journal:  Pharm Res       Date:  2012-06-16       Impact factor: 4.200

2.  Utility of Physiologically Based Pharmacokinetic Absorption Modeling to Predict the Impact of Salt-to-Base Conversion on Prasugrel HCl Product Bioequivalence in the Presence of Proton Pump Inhibitors.

Authors:  Jianghong Fan; Xinyuan Zhang; Liang Zhao
Journal:  AAPS J       Date:  2017-07-14       Impact factor: 4.009

Review 3.  Impact of excipient interactions on drug bioavailability from solid dosage forms.

Authors:  Ravikiran Panakanti; Ajit S Narang
Journal:  Pharm Res       Date:  2012-05-19       Impact factor: 4.200

4.  Enhancing and sustaining AMG 009 dissolution from a bilayer oral solid dosage form via microenvironmental pH modulation and supersaturation.

Authors:  Mingda Bi; Ali Kyad; Fernando Alvarez-Nunez; Francisco Alvarez
Journal:  AAPS PharmSciTech       Date:  2011-10-20       Impact factor: 3.246

5.  Enhancing and sustaining AMG 009 dissolution from a matrix tablet via microenvironmental pH modulation and supersaturation.

Authors:  Mingda Bi; Ali Kyad; Y-H Kiang; Yuan-Hon Kiang; Fernando Alvarez-Nunez; Francisco Alvarez
Journal:  AAPS PharmSciTech       Date:  2011-09-13       Impact factor: 3.246

6.  Salt stability--effect of particle size, relative humidity, temperature and composition on salt to free base conversion.

Authors:  Yi-Ling Hsieh; Lynne S Taylor
Journal:  Pharm Res       Date:  2014-08-22       Impact factor: 4.200

7.  Utilization of In Vitro, In Vivo and In Silico Tools to Evaluate the pH-Dependent Absorption of a BCS Class II Compound and Identify a pH-Effect Mitigating Strategy.

Authors:  Christoph Gesenberg; Neil R Mathias; Yan Xu; John Crison; Ishani Savant; Amy Saari; David J Good; Jeffrey N Hemenway; Ajit S Narang; Richard R Schartman; Naiyu Zheng; Adela Buzescu; Jatin Patel
Journal:  Pharm Res       Date:  2019-10-21       Impact factor: 4.200

8.  Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases.

Authors:  Peter Blomgren; Jayaraman Chandrasekhar; Julie A Di Paolo; Wanchi Fung; Guoju Geng; Carmen Ip; Randall Jones; Jeffrey E Kropf; Eric B Lansdon; Seung Lee; Jennifer R Lo; Scott A Mitchell; Bernard Murray; Chris Pohlmeyer; Aaron Schmitt; Kimberly Suekawa-Pirrone; Sarah Wise; Jin-Ming Xiong; Jianjun Xu; Helen Yu; Zhongdong Zhao; Kevin S Currie
Journal:  ACS Med Chem Lett       Date:  2020-02-12       Impact factor: 4.345

9.  Effect of Microenvironmental pH Modulation on the Dissolution Rate and Oral Absorption of the Salt of a Weak Acid - Case Study of GDC-0810.

Authors:  Hao Helen Hou; Wei Jia; Lichuan Liu; Sravanthi Cheeti; Jane Li; Ewa Nauka; Karthik Nagapudi
Journal:  Pharm Res       Date:  2018-01-29       Impact factor: 4.200

10.  Gamma scintigraphic study of the hydrodynamically balanced matrix tablets of Metformin HCl in rabbits.

Authors:  Mahboubeh Razavi; Hamed Karimian; Chai Hong Yeong; Sazilah Ahmad Sarji; Lip Yong Chung; Shaik Nyamathulla; Mohamed Ibrahim Noordin
Journal:  Drug Des Devel Ther       Date:  2015-06-19       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.